Watch DRMA. Know when insiders buy.
One email the day a filing lands. Free.
DRMA
Dermata Therapeutics, Inc.
1.19
−0.01 −0.83%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$8.4MNET CASH $4.4M52W 1.08 – 5.91SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$3M | −$3M | — | -0.74 | −$2.4M | — | — | Aug 11 |
| Q1 2026 · Mar 31 | — | — | — | −$1.9M | −$1.8M | — | -0.48 | −$2.5M | — | — | Aug 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$1.9M | −$1.9M | — | -1.52 | −$1.4M | — | — | Aug 11 |
| Q3 2025 · Sep 30 | — | — | — | −$1.8M | −$1.7M | — | -1.65 | −$1.8M | — | — | Nov 14 |
| Q2 2025 · Jun 30 | — | — | — | −$1.8M | −$1.7M | — | -1.66 | −$2.7M | — | — | Aug 11 |
| Q1 2025 · Mar 31 | — | — | — | −$2.3M | −$2.3M | — | -4.47 | −$1.9M | — | — | Aug 11 |
| Q4 2024 · Dec 31derived | — | — | — | −$3.2M | −$3.2M | — | 21.86 | −$2.9M | — | — | Mar 26 |
| Q3 2024 · Sep 30 | — | — | — | −$3.2M | −$3.2M | — | -20.41 | −$3.4M | — | — | Nov 14 |
| Q2 2024 · Jun 30 | — | — | — | −$2.9M | −$2.8M | — | -41.82 | −$2.1M | — | — | Nov 14 |
| Q1 2024 · Mar 31 | — | — | — | −$3.2M | −$3.1M | — | -7.06 | −$2.7M | — | — | Nov 14 |
| Q4 2023 · Dec 31derived | — | — | — | −$2.2M | −$2.1M | — | -37.53 | −$1.1M | — | — | Mar 17 |
| Q3 2023 · Sep 30 | — | — | — | −$1.8M | −$1.7M | — | -0.54 | −$1.8M | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$7.8M | −$7.6M | — | -8.16 | −$7.8M | — | — | — | — |
| FY2024 · to Dec 31 | — | — | −$12.5M | −$12.3M | — | -80.32 | −$11.2M | — | — | — | — |
| FY2023 · to Dec 31 | — | — | −$8M | −$7.8M | — | -39.99 | −$6.4M | — | — | — | — |
| FY2022 · to Dec 31 | — | — | −$9.7M | −$9.6M | — | -13.92 | −$8.8M | — | — | — | — |
| FY2021 · to Dec 31 | — | — | −$7.9M | −$7.9M | — | -2.43 | −$5.7M | — | — | — | — |
| FY2020 · to Dec 31 | — | — | −$3.2M | −$3.2M | — | -1.69 | −$4M | — | — | — | — |
Every number comes from Dermata Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.